These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 35426868

  • 1. Single-agent Bevacizumab in the Treatment of Symptomatic Newly Diagnosed and Recurrent/Refractory Pediatric Cervicomedullary Brainstem Low-grade Gliomas: A Single Institutional Experience.
    Sridhar S, Paul MR, Yeh-Nayre L, Khanna PC, Elster J, Aristizabal P, Crawford JR.
    J Pediatr Hematol Oncol; 2023 Jan 01; 45(1):e21-e25. PubMed ID: 35426868
    [Abstract] [Full Text] [Related]

  • 2. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep 01; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 3. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.
    J Pediatr Hematol Oncol; 2015 Aug 01; 37(6):e341-6. PubMed ID: 26056795
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.
    Neurology; 2008 Mar 04; 70(10):779-87. PubMed ID: 18316689
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
    Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K.
    Neuro Oncol; 2013 Jun 04; 15(6):650-5. PubMed ID: 23460324
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T.
    J Neurooncol; 2009 Feb 04; 91(3):329-36. PubMed ID: 18953493
    [Abstract] [Full Text] [Related]

  • 7. Antiangiogenic therapy for high-grade glioma.
    Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.
    Cochrane Database Syst Rev; 2014 Sep 22; (9):CD008218. PubMed ID: 25242542
    [Abstract] [Full Text] [Related]

  • 8. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B.
    Rev Neurol (Paris); 2008 Sep 22; 164(6-7):588-94. PubMed ID: 18565358
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M, Simeonovic M, Grommes C.
    Expert Opin Biol Ther; 2012 Aug 22; 12(8):1101-11. PubMed ID: 22663137
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
    Neuro Oncol; 2010 Sep 22; 12(9):985-90. PubMed ID: 20363768
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.
    Pediatr Blood Cancer; 2013 May 22; 60(5):776-82. PubMed ID: 22976922
    [Abstract] [Full Text] [Related]

  • 13. Bevacizumab at recurrence in high-grade glioma.
    Salmaggi A, Gaviani P, Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A.
    Neurol Sci; 2011 Nov 22; 32 Suppl 2():S251-3. PubMed ID: 21987287
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):2018-24. PubMed ID: 21489708
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
    Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P.
    Can J Neurol Sci; 2013 Mar 01; 40(2):241-6. PubMed ID: 23419575
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2010 Jan 01; 96(2):259-69. PubMed ID: 19593660
    [Abstract] [Full Text] [Related]

  • 20. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B.
    Pediatr Blood Cancer; 2009 Jul 01; 52(7):791-5. PubMed ID: 19165892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.